ALFA Filings
Every announcement, straight from the exchange
Every Mankind Pharma debt & borrowing announcement on NSE and BSE, newest first, each with its own page.
Time
6 announcements
Mankind Pharma has successfully completed the interest payment and full redemption of its Non-Convertible Debentures due on October 16, 2026.
Mankind Pharma has fully redeemed its Non-Convertible Debentures, paying back the principal amount of ₹1,250 Crore on the maturity date.
Mankind Pharma Ltd confirmed payment of interest for its non-convertible debentures. This routine debt servicing update confirms the company has fulfilled its payment obligations.
Mankind Pharma approved a ₹150 Crore corporate guarantee in favour of banks for Bharat Serums and Vaccines Limited's credit facilities. This contingent liability supports BSV's operations.
Mankind Pharma Ltd has completed the redemption of NCDs (INE634S07017) and paid total interest of ₹198.95 Crore across three NCD series on April 16, 2026. The total outflow for redemption and interest payments amounted to ₹1,448.95 Crore. This fulfills the company's scheduled debt obligations and reduces outstanding non-convertible debenture liabilities.
Mankind Pharma Limited submitted a half-yearly statement for its listed privately placed debt securities ending March 31, 2026. The disclosure tracks three NCD series totalling ₹5,000 Crore in outstanding principal, with coupon rates between 7.97% and 7.99%.